TABLE 2.

Summary of number of samples selected^a

Groups	N
Negativeb	30
Low positive-infected original strain	12
Intermediate positive-infected original strain	12
High positive-infected original strain	12
Infected variant	5
Low positive-vaccinated	16
Intermediate positive-vaccinated	15
High positive-vaccinated	15
Anti-SAR-CoV-2 RBD mAb	2
Diluted WHO international standard	1
US Serology Standard	1
Total	121

^aSamples were from unique individuals.

^bCollected from subjects who were unvaccinated and uninfected with SARS-CoV-2, and these samples were used for assay cutoff evaluations.